Literature DB >> 27687005

Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Seung-Myoung Son1, Sang-Yun Ha1, Hae-Yong Yoo2,3, Dongryul Oh4, Seok-Jin Kim3,5, Won-Seog Kim3,5, Young-Hyeh Ko1,3.   

Abstract

The prognostic role of MYC has been well documented in non-central nervous system diffuse large B-cell lymphoma; however, it remains controversial in central nervous system diffuse large B-cell lymphoma. To investigate the prognostic value of MYC, we analyzed the MYC protein expression by immunohistochemistry, mRNA expression by RNA in situ hybridization, and gene status by fluorescence in situ hybridization in 74 cases of central nervous system diffuse large B-cell lymphoma. Moreover, we examined the correlation between MYC translocation, mRNA expression, and protein expression. The mean percentage of MYC immunopositive cells was 49%. Using a 44% cutoff value, 49 (66%) cases showed MYC protein overexpression. The result of mRNA in situ hybridization using the RNA scope technology was obtained using the H-scoring system; the median value was 34.2. Using the cutoff value of 63.5, 16 (22%) cases showed MYC mRNA overexpression. MYC gene rearrangement was detected in five out of 68 (7%) cases. MYC translocation showed no statistically significant correlation with mRNA expression; however, all MYC translocation-positive cases showed MYC protein overexpression, with a higher mean percentage of MYC protein expression than that of translocation-negative cases (78 vs 48%, P=0.001). The level of MYC mRNA expression was moderately correlated with the level of MYC protein expression (P<0.001). The mean percentage of MYC protein expression in the high MYC mRNA group was higher than that in the low MYC mRNA group (70 vs 47%, P<0.001). A univariate analysis showed that age over 60 years, Eastern Cooperative Oncology Group (ECOG) performance status ≥2 and MYC protein overexpression were significantly associated with an increased risk of death. MYC translocation and MYC mRNA expression had no prognostic significance. On multivariate analysis, MYC protein overexpression and ECOG score retained prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27687005     DOI: 10.1038/modpathol.2016.56

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  48 in total

1.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

3.  Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.

Authors:  Nicky D'Haene; Xavier Catteau; Calliope Maris; Benoit Martin; Isabelle Salmon; Christine Decaestecker
Journal:  Br J Haematol       Date:  2007-12-13       Impact factor: 6.998

4.  Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma.

Authors:  Do Hyoung Lim; Won Seog Kim; Seok Jin Kim; Hae Yong Yoo; Young Hyeh Ko
Journal:  Anticancer Res       Date:  2015-06       Impact factor: 2.480

5.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Miaoxia He; Changjing Zuo; Jianjun Wang; Jianmin Liu; Binghua Jiao; Jianmin Zheng; Zailong Cai
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

7.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas.

Authors:  Anna Brunn; Inga Nagel; Manuel Montesinos-Rongen; Wolfram Klapper; Inga Vater; Werner Paulus; Volkmar Hans; Ingmar Blümcke; Joachim Weis; Reiner Siebert; Martina Deckert
Journal:  Acta Neuropathol       Date:  2013-09-06       Impact factor: 17.088

9.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

View more
  7 in total

1.  Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.

Authors:  Diego Villa; King L Tan; Christian Steidl; Susana Ben-Neriah; Muntadhar Al Moosawi; Tamara N Shenkier; Joseph M Connors; Laurie H Sehn; Kerry J Savage; David W Scott; Randy D Gascoyne; Graham W Slack
Journal:  Blood Adv       Date:  2019-12-10

2.  The Bioinformatical Identification of Potential Biomarkers in Heart Failure Diagnosis and Treatment.

Authors:  Xiaodong Sheng; Xiaoqi Jin; Yanqi Liu; Tao Fan; Zongcheng Zhu; Jing Jin; Guanqun Zheng; Zhixian Chen; Min Lu; Zhiqiang Wang
Journal:  Genet Res (Camb)       Date:  2022-05-16       Impact factor: 1.375

Review 3.  Advances in Pathobiology of Primary Central Nervous System Lymphoma.

Authors:  Xue-Liang Yang; Yuan-Bo Liu
Journal:  Chin Med J (Engl)       Date:  2017-08-20       Impact factor: 2.628

Review 4.  Role of MYC in B Cell Lymphomagenesis.

Authors:  Petra Korać; Snježana Dotlić; Maja Matulić; Matea Zajc Petranović; Mara Dominis
Journal:  Genes (Basel)       Date:  2017-04-04       Impact factor: 4.096

Review 5.  Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.

Authors:  Marietya I S Lauw; Calixto-Hope G Lucas; Robert S Ohgami; Kwun Wah Wen
Journal:  Diagnostics (Basel)       Date:  2020-12-11

6.  Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.

Authors:  Jinuk Kim; Tae Gyu Kim; Hyoun Wook Lee; Seok Hyun Kim; Ji Eun Park; Moonok Lee; Young Zoon Kim
Journal:  Curr Oncol       Date:  2021-11-12       Impact factor: 3.677

7.  Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma.

Authors:  Anthony Jacquier; Charlotte Syrykh; Isabelle Bedgedjian; Franck Monnien; Camille Laurent; Séverine Valmary-Degano; Pierre Brousset
Journal:  J Clin Pathol       Date:  2020-08-24       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.